Skip to main content

2023–2024 RSV Season and Synagis Prior Authorization Ended March 15, 2024, for All Regions

Last updated on

The Texas Health and Human Services Commission (HHSC) closed the 2023–2024 respiratory syncytial virus (RSV) season’s Synagis prophylaxis therapy for all regions on March 15, 2024.

HHSC based this decision on the recommendation of the Texas RSV task force and the HHSC Office of the Medical Director (OMD) because of the continued decrease in positive RSV tests in the past two consecutive weeks. HHSC, in collaboration with the RSV task force and the OMD, will continue to monitor RSV activities and notify the public about any updates needed to allow access to Synagis prophylaxis treatments.

HHSC does not cover RSV vaccines through pharmacy benefits, and this notice does not impact the vaccination of eligible members through the Texas Vaccines for Children (TVFC) program.

Email vdp-formulary@hhsc.state.tx.us with any questions.